Goblet - Pancreatic Cancer // Adlai Nortye Acquisition.
The current market is giving zero value for the Goblet / Pancreatic Cancer trial.
Management gave an idea of what they would do (going directly to a pivotal randomized trial) with FDA feeback under the accelarated designation.
An official press release detailing the trial layout and FDA discussion would generate share price appreciation.
Also, final results for Goblet Pancreatic Cancer trial would also generate hare price appreciation.
Both these events are not mentionned in the near term catalyst but could happen in the coming months.
So, my game plan is to add even more as this stock is nearing an imminent deal.
Finally, I bet that Adlai Nortye will acquire ONCY and make it their flagship plateform drug. It would be a big win for China and they do want to dominate as many markets as possible. They will move first and fast as they are already minority shareholders here.
I will let the market digest this event and price it in.